Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/6dgx4f02

INTEGRATING AYURVEDIC PRINCIPLES INTO MODERN PALLIATIVE CANCER CARE: A NARRATIVE REVIEW

Dr Rashmi Gupta

*Associate professor, Department of Shalya Tantra, Faculty of Ayurveda, Institute of Medical sciences, Banaras Hindu University, Varanasi, 221005

Abstract

Background: The global burden of advanced cancer is characterized by significant symptom distress and unmet supportive care needs. Modern palliative care, while essential, may be supplemented by holistic traditional systems. Ayurveda, a personalized, whole-system traditional medicine from India, aligns conceptually with palliative care goals.

Objective: This narrative review explores the theoretical foundations of Ayurveda, its potential integration into palliative cancer care for symptom management and psychosocial support, and evaluates the existing evidence base.

Methods: A narrative synthesis of peer-reviewed literature from PubMed, Scopus, and AYUSH research portals was conducted, focusing on Ayurvedic principles, clinical studies in oncology/palliative care, and integrative medicine frameworks.

Results: Ayurveda's core principles—individual constitution (*Prakriti*), bio-energetic balance (*Doshas*), and holistic health—resonate with the biopsychosocial-spiritual model of palliative care. Preliminary evidence suggests potential benefits of specific interventions: *Rasayana* (rejuvenation) herbs (e.g., *Withania somnifera*) for cancer-related fatigue; mind-body practices (yoga, meditation) for anxiety and depression; herbal and dietary strategies for gastrointestinal symptoms; and adjuvant herbal analgesics (e.g., *Boswellia serrata*) for pain. Major challenges include a limited high-quality clinical evidence base, safety concerns regarding herb-drug interactions, and a lack of standardized integrative care models.

Conclusions: Ayurveda offers a patient-centered, holistic framework that may complement conventional palliative oncology care. While current evidence is encouraging but preliminary, rigorous clinical research, interdisciplinary collaboration, and standardized safety protocols are needed to responsibly integrate these approaches. Thoughtful synthesis of Ayurvedic principles with modern palliative care holds promise for enhancing the quality of life and addressing the multidimensional suffering of patients with advanced cancer.

Keywords: Ayurveda; Palliative Care; Cancer; Integrative Oncology; Quality of Life; Complementary Medicine; Symptom Management

Introduction

Cancer remains a formidable global health challenge, responsible for an estimated 19.3 million new cases and nearly 10.0 million deaths annually (1). While advances in early detection and targeted therapies have improved survival outcomes for many malignancies, a substantial proportion of patients with advanced disease continue to endure a significant burden of physical and psychological symptoms throughout their illness trajectory (2). Pain, fatigue, nausea, anorexia,

anxiety, and depression are pervasive, contributing to profound suffering and diminished quality of life (QOL) (3).

In response to this unmet need, palliative care has been established as an indispensable component of comprehensive oncology. Defined by the World Health Organization (WHO) as "an approach that improves the quality of life of patients and their families facing the problem associated with life-threatening illness," modern palliative care addresses suffering through the prevention and relief of symptoms via a holistic, biopsychosocial-spiritual model (4). This model recognizes that effective care must extend beyond tumor control to encompass the multidimensional needs of the individual (5). The integration of palliative care early in the cancer continuum is now strongly supported by evidence demonstrating improved QOL, reduced depressive symptoms, and even prolonged survival in some populations (6, 7).

Parallel to these developments in conventional medicine, there has been a significant rise in the use of traditional and complementary medicine (T&CM) among patients with cancer. Studies indicate that up to 80% of oncology patients utilize some form of T&CM, often seeking greater symptom control, reduced side effects from conventional treatments, enhanced well-being, and a more active, participatory role in their care (8, 9). Ayurveda, a sophisticated system of medicine with a documented history spanning over three millennia in the Indian subcontinent, represents one of the world's most ancient and holistic healing traditions (10). Its foundational philosophy posits health as a dynamic state of equilibrium between the individual's body, mind, and consciousness (*Purusha*), and their environment. This is operationalized through concepts such as individual constitution (*Prakriti*), functional bio-energies (*Doshas*), and therapeutic modalities ranging from herbal medicine and diet to yoga and meditation (11).

The core tenets of Ayurveda—individualization, holism, promotion of balance, and emphasis on preventive and supportive care—demonstrate a remarkable conceptual synergy with the goals of modern palliative oncology (12). Both systems prioritize patient-centered goals, dignity, and the alleviation of multi-dimensional suffering. This alignment suggests that the judicious integration of Ayurvedic principles and practices could offer valuable adjunctive tools to address complex symptom clusters and existential distress that are often refractory to conventional approaches alone.

This narrative review, therefore, aims to: 1) elucidate the foundational principles of Ayurvedic medicine; 2) examine the theoretical congruence between Ayurveda and palliative care; 3) critically appraise the existing clinical evidence for Ayurvedic interventions in managing common cancer-related symptoms; and 4) discuss the practical, ethical, and research imperatives for safe and effective integration into contemporary palliative cancer care frameworks.

Overview of Ayurvedic Principles

Theoretical Foundations and Diagnostic Framework

The theoretical edifice of Ayurveda is built upon several interconnected core doctrines that inform its unique understanding of health, disease, and therapy.

1. **The *Panchamahabhuta* (Five Great Elements):** All matter, including the human body, is composed of a combination of five fundamental elements: *Akasha* (space/ether), *Vayu* (air), *Tejas/Agni* (fire), *Jala* (water), and *Prithvi* (earth) (13). These elements manifest in biological functions through the three *Doshas*.
2. **The *Tridosha* Theory:** The three *Doshas—Vata*, *Pitta*, and *Kapha*—are biological humors or functional principles that govern all physiological and psychological processes. Each is a unique combination of the *Mahabhutas*:

a. ***Vata*** (composed of Space and Air) governs movement, including nerve impulses, circulation, respiration, and elimination. Its qualities are dry, light, cold, rough, subtle, and mobile.
b. ***Pitta*** (composed of Fire and Water) governs transformation, metabolism, digestion, and temperature homeostasis. Its qualities are hot, sharp, liquid, slightly oily, and mobile.
c. ***Kapha*** (composed of Earth and Water) governs structure, cohesion, stability, and lubrication. Its qualities are heavy, slow/dull, cool, oily, smooth, and dense (14). Every individual has a unique, inherent proportion of these three doshas established at

conception, known as their ***Prakriti*** (constitution). This *Prakriti* determines an individual's physical characteristics, physiological tendencies, temperament, and susceptibility to specific diseases (15).

3. ***Dhatus*** **(Bodily Tissues),** ***Malas*** **(Waste Products), and** ***Agni*** **(Metabolic Fire):**

a. ***Sapta Dhatus*** are the seven sequential tissue layers (*Rasa* - plasma, *Rakta* - blood, *Mamsa* - muscle, *Meda* - fat, *Asthi* - bone, *Majja* - marrow/nervous tissue, and *Shukra/Artava* - reproductive tissue) that nourish the body (16).

b. ***Malas*** are the waste products of metabolism (primarily feces, urine, sweat) whose proper formation and timely elimination are critical for health.

c. ***Agni***, the pivotal concept of metabolic fire, is responsible for all digestive and transformative processes—from digesting food to transforming it into *Dhatus*, and even processing sensory and emotional experiences. Impaired *Agni* leads to the production of *Ama*, undigested toxic material considered a root cause of disease (17).

Disease Etiology and Pathogenesis

Ayurvedic pathology (*Samprapti*) describes disease as a six-stage process beginning with the accumulation of a dosha due to causative factors (*Nidana*) like improper diet (*Ahara*), lifestyle (*Vihara*), or seasonal influences, and culminating in its manifestation (*Vyakti*) as recognizable symptoms in specific organs or systems (18). The ultimate goal of diagnosis is to identify the nature of the doshic imbalance (*Vikriti*), the location of the disease, and the strength of the patient.

Therapeutic Modalities

Treatment (*Chikitsa*) is profoundly individualized, aiming to restore the innate *Prakriti* by pacifying the aggravated doshas and eliminating *Ama*. The therapeutic spectrum is vast and is often employed in combination:

1. ***Ahara*** **(Dietary Therapy):** Food is considered the foremost medicine. Dietary prescriptions are meticulously tailored based on a patient's *Prakriti*, the state of their *Agni*, the nature of their illness, and the season. Specific tastes (*Rasa*), qualities (*Guna*), and post-digestive effects (*Vipaka*) of foods are used therapeutically (19).
2. ***Vihara*** **(Lifestyle and Behavioral Regimens):** This includes daily routines (*Dinacharya*) for maintaining health, seasonal regimens (*Ritucharya*), and advice on sleep, exercise, and ethical living. Gentle physical practices like yoga are integral.
3. ***Aushadhi*** **(Herbal and Herbo-Mineral Pharmaceuticals):** Ayurveda utilizes a sophisticated pharmacopoeia of single herbs (*Dravya*) and complex polyherbal/mineral formulations. These are processed (*Samskara*) and prescribed based on their taste (*Rasa*), potency (*Virya*), post-digestive effect (*Vipaka*), and specific therapeutic action (*Prabhava*) to correct imbalances (20).
4. ***Panchakarma*** **(Bio-purification Procedures):** This is a cornerstone of classical Ayurvedic treatment, consisting of five primary detoxification actions: therapeutic emesis (*Vamana*), purgation (*Virechana*), medicated enema (*Basti*), nasal administration of medicines (*Nasya*), and bloodletting (*Rakta Mokshana*). In the context of palliative care for advanced cancer, the focus shifts to the preparatory (*Purvakarma*) and supportive aspects, such as oleation (*Snehana*) with internal or external medicated oils and gentle sudation (*Swedana*), which are considered nourishing and comforting (21).

5. ***Satvavajaya Chikitsa*** **(Psychotherapy) and** ***Adravyabhuta Chikitsa*** **(Non-Pharmacological Therapies):** This branch focuses on mind-body medicine, using techniques like meditation (*Dhyana*), breath control (*Pranayama*), and counseling to cultivate mental clarity (*Sattva*), restrain the mind from unwholesome thoughts, and promote psychological and spiritual well-being (22).

This comprehensive, principle-based system provides a structured framework for understanding an individual's state of health and for applying multi-modal interventions aimed at restoring balance, which is intrinsically aligned with the supportive and holistic goals of palliative care.

Symptom Management in Palliative Cancer Care: Potential Ayurvedic Applications

The symptom burden in advanced cancer is multidimensional and often refractory to conventional monotherapies. Ayurveda's holistic, individualized framework offers adjunctive strategies that target not only the physical symptom but also the underlying doshic imbalance and the patient's overall vitality. The following section details the application of Ayurvedic principles to common palliative care symptoms.

Pain

Cancer-related pain is complex, involving inflammatory, neuropathic, and mechanical components. The WHO analgesic ladder, while foundational, can be limited by side effects such as constipation, sedation, and opioid-induced hyperalgesia.

A. **Ayurvedic Perspective:** Pain (*Shula*) is primarily attributed to the vitiation of *Vata Dosha*, whose mobile, subtle, and dry qualities disrupt the normal flow of energy (*Prana*) and cause obstruction (*Avarana*) in the microchannels (*Srotas*). It can also be associated with aggravated *Pitta* (burning pain) or *Kapha* (dull, heavy ache) (23).

B. **Potential Interventions:**

a. ***Abhyanga* (Therapeutic Massage):** A cornerstone of *Vata*-pacifying therapy, gentle massage with warm, medicated oils (e.g., *Mahanarayan* oil, *Bala Ashwagandha* oil) can reduce muscle tension, improve circulation, provide comforting touch, and promote relaxation, thereby modulating the pain experience (24).

b. **Herbal Analgesics & Anti-Inflammatories:**

I ***Ashwagandha (Withania somnifera):*** A primary *Rasayana* (rejuvenative) with documented anti-inflammatory and analgesic properties. It may also help modulate neuropathic pain and counter opioid tolerance (25).

II ***Shallaki (Boswellia serrata):*** The resin contains boswellic acids, potent inhibitors of 5-lipoxygenase and leukotriene synthesis, shown in clinical studies to reduce inflammation and pain in conditions like osteoarthritis and may benefit bone pain (26).

III ***Guggulu (Commiphora wightii):*** Used traditionally for inflammatory conditions, its gum resin has demonstrated anti-arthritic and anti-nociceptive effects in preclinical models (27).

IV ***Turmeric (Curcuma longa):*** Curcumin, its active compound, is a well-researched anti-inflammatory agent that modulates NF-κB and COX-2 pathways, potentially useful as an adjuvant for inflammatory pain (28).

c. ***Lepa* (Medicated Poultices):** Topical application of pastes made from herbs like sandalwood or *Yashtimadhu (Glycyrrhiza glabra)* can provide localized cooling or analgesic effects.

C. **Integration:** These modalities serve as adjuncts to conventional analgesia. For instance, *Abhyanga* and *Ashwagandha* may reduce the required opioid dose and mitigate associated side effects. Monitoring for herb-drug interactions (e.g., *Ashwagandha* with sedatives) is essential.

Cancer-Related Fatigue (CRF) and Cachexia

CRF is a pervasive, distressing sense of physical, emotional, and cognitive exhaustion not proportional to activity. Cachexia involves involuntary weight loss and muscle wasting.

A. **Ayurvedic Perspective:** Fatigue (*Shrama*, *Daurbalya*) is viewed as a depletion of vital energy and essence (*Ojas*), often stemming from impaired *Agni* (leading to poor tissue nutrition), excessive tissue consumption (*Dhatu Kshaya*), or aggravated *Vata* or *Kapha* (29).

B. **Potential Interventions:**

a. ***Rasayana* (Rejuvenation) Therapy:** The primary Ayurvedic strategy for restoring energy, strength, and immunity.

I ***Ashwagandha (Withania somnifera):*** The premier adaptogen for fatigue. A randomized controlled trial in breast cancer patients showed significant improvement in fatigue scores and QOL compared to placebo (30).
II ***Guduchi (Tinospora cordifolia):*** An immunomodulator and *Rasayana* known for its anti-fatigue and energy-enhancing properties (31).

b. ***Brimhana*** **(Nourishing) Therapy:** Involves a nutrient-dense, easily digestible diet using substances like milk, ghee, and soups to counteract tissue wasting. Dietary counseling focuses on strengthening *Agni*.
c. *Yoga:* Gentle, modified *Yoga* practices, incorporating postures (*Asanas*), breath control (*Pranayama*), and meditation, have Level 1 evidence for reducing fatigue and improving sleep and QOL in cancer populations (32).
C. **Integration:** *Rasayana* herbs like *Ashwagandha* and a gentle yoga program can be integrated as core components of a non-pharmacologic CRF management plan, alongside nutritional support and energy conservation strategies.

Gastrointestinal Symptoms
Nausea, vomiting, anorexia, constipation, and mucositis are extremely common due to cancer, chemotherapy, or opioids.
A. **Ayurvedic Perspective:** Nearly all GI symptoms are rooted in impaired digestive fire (*Mandagni*), leading to the production of *Ama* (toxins). Symptoms reflect specific doshic imbalances: nausea/vomiting (*Chhardi*) with *Kapha* or *Pitta*; constipation (*Vibandha*) with *Vata* (33).

B. **Potential Interventions:**
a. **Dietary & Lifestyle (*Ahara-Vihara*) Modifications:** Core therapy. Principles include eating warm, moist, freshly cooked foods; consuming ginger or cumin water before meals to kindle *Agni*; and avoiding incompatible food combinations (*Viruddha Ahara*) like dairy with fruit.

b. **Herbal Support:**
I. **Nausea/Vomiting: *Ginger (Zingiber officinale)*** and ***Licorice (Yashtimadhu)*** are well-studied for antiemetic effects (34). ***Cumin (Cuminum cyminum)*** and ***Coriander (Coriandrum sativum)*** seeds in water are traditional remedies.
II. **Anorexia/Digestive Stimulation: *Trikatu*** (a blend of ginger, black pepper, and long pepper) is a classic formulation to strengthen *Agni*.
III. **Constipation: *Triphala*** (a balanced blend of *Amalaki*, *Bibhitaki*, *Haritaki*) acts as a gentle, non-habit-forming bowel regulator and mild laxative, also exhibiting antioxidant properties (35).
IV. **Mucositis/Stomatitis:** Gargling with cooled infusions of ***Licorice*** **or** ***Aloe vera*** **juice** can soothe oral mucosa. Topical application of honey or ghee is also used.
C. **Integration:** Ayurvedic dietary advice and select herbs can be highly effective complements to standard antiemetics, appetite stimulants, and laxatives. *Triphala*, for example, may help manage opioid-induced constipation.

Psycho-Spiritual Symptoms: Anxiety, Depression, and Sleep Disturbances
Psychological morbidity significantly impacts QOL and is linked to poorer outcomes.
A. **Ayurvedic Perspective:** Mental health is governed by the balance of the three mental qualities (*Gunas*): *Sattva* (clarity, peace), *Rajas* (activity, agitation), and *Tamas* (inertia, darkness). Anxiety and insomnia reflect excess *Rajas*, while depression reflects excess *Tamas*. Therapy (*Satvavajaya*) aims to cultivate *Sattva* (36).

B. **Potential Interventions:**
a. ***Pranayama* (Breath Control):** Techniques like ***Nadi Shodhana*** (alternate nostril breathing) have demonstrated acute anxiolytic effects and improve autonomic balance (37). ***Bhramari*** (bee breath) promotes relaxation.
b. **Meditation (*Dhyana*):** Mindfulness-based practices derived from this tradition are extensively validated for reducing anxiety, depressive symptoms, and fear of cancer recurrence (38).
c. ***Yoga*:** As an integrated mind-body practice, yoga improves mood, sleep quality, and overall psychological well-being in cancer patients (32).
d. **Herbal Support:** ***Ashwagandha*** has shown significant anxiolytic and antidepressant effects in clinical trials, likely through GABAergic activity and cortisol modulation (39). ***Brahmi (Bacopa monnieri)*** is a traditional nervine tonic for cognitive function and anxiety.
C. **Integration:** These mind-body interventions are highly congruent with palliative psychosocial support and can be seamlessly incorporated. They empower patients with self-management tools for distress.

Evidence Base and Clinical Studies
The clinical evidence supporting the integration of Ayurvedic interventions into palliative oncology is characterized by promising pilot data, but is limited by small-scale studies, methodological heterogeneity, and a lack of large, definitive randomized controlled trials (RCTs). The evidence base for specific mind-body practices like yoga and meditation—while often studied outside of a strictly Ayurvedic framework—is more robust and provides a strong rationale for their inclusion. This section reviews the state of the evidence across key domains.

Clinical Trials in Symptom Management and Quality of Life
A growing number of small RCTs and uncontrolled pilot studies have investigated specific Ayurvedic herbs and protocols in cancer care.
1. **Cancer-Related Fatigue (CRF) and Quality of Life:**
a. **Ashwagandha:** The most studied Ayurvedic herb in oncology. A 2013 RCT in breast cancer patients undergoing chemotherapy found that a standardized *Ashwagandha* root extract (2g, thrice daily) led to significant improvements in general health, social, and emotional well-being scales on the FACT-B instrument, as well as reduced fatigue compared to placebo (30). Another RCT in patients receiving adjuvant chemotherapy or radiotherapy found *Ashwagandha* significantly reduced fatigue severity and improved QOL (40).
b. **Multi-Modal Approaches:** A 2017 pilot RCT of a comprehensive Ayurvedic protocol (including diet, herbs like *Ashwagandha* and *Guduchi*, and yoga) for women with breast cancer receiving chemotherapy showed significant improvements in physical and functional well-being, and a trend toward reduced fatigue, compared to usual care alone (41).

2. **Psychological Distress:**
a. **Mind-Body Interventions:** While not always labeled "Ayurvedic," practices central to Ayurveda, such as yoga and meditation, have a strong evidence base. Multiple meta-analyses confirm that yoga interventions significantly reduce anxiety and depressive symptoms and improve overall QOL in cancer patients (32, 42).
b. **Herbal Support:** Clinical trials outside of oncology support the anxiolytic potential of *Ashwagandha*. A 2012 RCT in adults with chronic stress found a high-concentration *Ashwagandha* extract significantly reduced stress and anxiety scores on validated scales compared to placebo (39). Similar effects have been demonstrated for *Bacopa monnieri* (43).

3. **Pain and Inflammation:**
a. **Herbal Analgesics:** Clinical evidence specific to cancer pain is sparse. However, trials for inflammatory pain conditions are supportive. RCTs of *Boswellia serrata* extract in osteoarthritis have shown significant reductions in pain and stiffness and improved physical function (44).

Preclinical models suggest *Ashwagandha* has anti-nociceptive properties, potentially through GABA-mimetic activity (45).

4. **Gastrointestinal Symptoms:**

a. Evidence for Ayurvedic herbs often overlaps with general herbal medicine research. For instance, ginger (*Zingiber officinale*) is a well-established antiemetic, with RCTs supporting its efficacy in reducing chemotherapy-induced nausea and vomiting (34). *Triphala*'s gentle laxative effect is supported by traditional use and some clinical studies in functional constipation (35).

Observational, Qualitative, and Mixed-Methods Studies

These studies provide important insights into patient experience, cultural relevance, and real-world integration.

a. **Qualitative Analyses:** Studies exploring patient perspectives reveal that the appeal of Ayurveda lies in its holistic, individualized, and empowering approach. Patients often report feeling "cared for as a whole person," valuing the time spent in consultation, the focus on diet and lifestyle, and the sense of agency it provides—elements that directly address psychosocial and existential dimensions of palliative care (46).

b. **Mixed-Methods Research:** Studies examining integrative clinics in India and elsewhere report improvements in patient-reported symptoms and QOL, alongside high satisfaction. They highlight the importance of the therapeutic relationship and the non-pharmacological aspects of care (47).

Methodological Limitations and Challenges

The current evidence has significant constraints that must be acknowledged:

1. **Lack of Standardization:** A major barrier to research and clinical application is the variability in herbal formulations. The quality, potency, and composition of herbal products can differ vastly between manufacturers and even batches, making it difficult to compare study results or ensure consistent clinical effects (48).

2. **Inadequate Study Design:** Many existing studies suffer from small sample sizes, short follow-up periods, lack of appropriate blinding (difficult with complex dietary/lifestyle interventions), and high risk of bias. There is a notable absence of large, multi-center, Phase III RCTs for most Ayurvedic interventions in palliative oncology.

3. **Outcome Measures:** Many studies rely on generic QOL tools, which may not capture the subtle, culturally specific improvements in well-being targeted by Ayurveda (e.g., improved *Agni*, sense of balance). Developing and validating cross-culturally relevant, patient-centered outcome measures is a key need (49).

4. **Safety Reporting:** Systematic reporting of adverse events and herb-drug interactions in clinical trials is often inadequate. Much of the safety data comes from case reports or pharmacovigilance studies (50).

Safety and Herb-Drug Interactions

Safety is a paramount concern, particularly in medically complex palliative care patients.

A. **Potential Interactions:** Key concerns include:

a. **Immunostimulant Herbs** (e.g., *Guduchi*): Theoretical risk of interfering with immunosuppressive chemotherapy, though clinical evidence is lacking.

b. **Hepatoprotective/Metabolism-Modifying Herbs:** Herbs like *Turmeric* (curcumin) and *Kutki (Picrorhiza kurroa)* may affect cytochrome P450 enzymes, potentially altering the metabolism of chemotherapeutic agents (51).

c. **Sedative Herbs:** *Ashwagandha* may potentiate the effects of benzodiazepines, barbiturates, and other sedatives.

d. **Anticoagulant Effects:** Herbs like *Guggulu* and *Turmeric* may have mild antiplatelet activity, posing a theoretical risk when combined with anticoagulants like warfarin.

B. **Quality Control:** Risks of contamination with heavy metals, pesticides, or adulterants with conventional pharmaceuticals remain a serious issue, emphasizing the need for sourcing from reputable, standardized suppliers (52).

Evidence: The existing clinical evidence, while preliminary, provides a sufficient rationale to warrant further rigorous investigation of Ayurvedic interventions in palliative oncology. The strongest support is for mind-body practices (yoga, meditation) and select *Rasayana* herbs like *Ashwagandha* for fatigue and QOL. Safe integration requires an evidence-informed approach, prioritizing interventions with the most favorable risk-benefit profile, close monitoring for interactions, and collaborative care within an interdisciplinary team.

Ethical, Cultural, and Practical Considerations

The integration of Ayurveda into modern palliative cancer care extends beyond clinical efficacy into complex ethical, cultural, and practical domains. Successful and responsible integration requires navigating these considerations with sensitivity, professionalism, and a commitment to patient-centered ethics.

Ethical Imperatives

1. **Patient Autonomy and Informed Consent:** Central to ethical integration is respect for patient autonomy. Patients must be empowered to make informed choices about incorporating Ayurvedic care. This requires clear, transparent communication about:
   a. **The Nature of Ayurveda:** Explaining it as a holistic system with a different philosophical basis than biomedicine.
   b. **Evidence Base:** Honestly presenting the state of evidence—highlighting promising areas (e.g., yoga for fatigue, *Ashwagandha* for QOL) while acknowledging limitations and uncertainties for other interventions.
   c. **Potential Risks:** Explicitly discussing risks of herb-drug interactions, variability in product quality, and the potential for delaying or replacing proven conventional treatments.
   d. **Financial Implications:** Disclosing costs, as these therapies are often not covered by insurance, to prevent financial toxicity (53).
   e. Consent should be an ongoing process, documented in the medical record.
2. **Non-Maleficence and Safety:** The principle of "first, do no harm" is paramount. Key safety strategies include:
   a. **Systematic Screening:** Implementing routine screening for T&CM use in palliative care assessments.
   b. **Herb-Drug Interaction Databases:** Utilizing resources like the Natural Medicines Comprehensive Database to check for potential interactions with chemotherapy, targeted therapies, opioids, and anticoagulants.
   c. **Vigilance for Quality:** Recommending the use of standardized, clinically tested herbal extracts from reputable manufacturers that adhere to Good Manufacturing Practices (GMP) to mitigate risks of contamination and adulteration (52).
   d. **Contraindication for Frailty:** Avoiding aggressive detoxification procedures (*Panchakarma*) like strong emesis or purgation in patients with advanced cachexia, cytopenias, or organ failure.
3. **Professional Boundaries and Scope of Practice:** Palliative care clinicians are not expected to become Ayurvedic experts. Their ethical duty is to:
   a. Maintain a non-judgmental, open attitude towards patient choices.
   b. Provide balanced, evidence-informed counseling.
   c. Recognize the limits of their knowledge and refer to or collaborate with qualified Ayurvedic practitioners when appropriate.

Cultural Competence and Sensitivity

1. **Respecting Worldviews:** Ayurveda is not merely a set of therapies; it is embedded in a specific cultural and philosophical worldview that connects health, cosmology, and spirituality. For many

patients, particularly from South Asian backgrounds, it is an integral part of their cultural identity and approach to healing. Effective palliative care requires respecting these beliefs without stereotyping or making assumptions (54).

2. **Avoiding Medical Paternalism and "Othering":** Dismissing Ayurveda as unscientific or merely "alternative" can alienate patients and violate cultural humility. Conversely, uncritical romanticization of "Eastern wisdom" is also inappropriate. The goal is a collaborative, patient-led dialogue that honors the patient's explanatory model for their illness.

3. **Culturally Sensitive Communication:** This involves using interpreters when needed, understanding cultural norms around illness disclosure and decision-making (which may be more family-centric), and being aware of dietary and ritual practices that hold significance for the patient.

Practical and Logistical Challenges

1. **Interdisciplinary Collaboration Model:** Safe integration requires a structured collaborative framework. Ideal models involve:

a. **Co-Located or Networked Care:** Where an Ayurvedic physician (Vaidya) trained in integrative oncology works within or in formal consultation with the palliative care/oncology team.

b. **Clear Communication Channels:** Establishing protocols for shared medical records (with patient consent), regular case conferences, and defined roles. The palliative care physician remains the lead for overall symptom control and end-of-life care.

c. **Shared Care Plans:** Developing integrated treatment plans that specify which symptoms are addressed by which modality, with clear monitoring parameters.

2. **Education and Training Gaps:**

a. **For Conventional Providers:** Most receive no training in Ayurvedic principles or how to counsel patients about T&CM. Incorporating basic modules on major traditional systems, communication skills, and safety into palliative medicine and oncology curricula is essential (55).

b. **For Ayurvedic Practitioners:** Training in modern oncology and palliative care principles, pharmacology of cancer drugs, recognition of oncologic emergencies, and the ethics of informed consent is crucial for those wishing to work in integrative settings.

3. **Regulatory and Standardization Issues:** The regulatory landscape for Ayurvedic medicines varies dramatically by country.

a. In India, the AYUSH ministry regulates education and practice, but quality control remains inconsistent.

b. In the US and EU, Ayurvedic products are typically regulated as dietary supplements, not medicines, leading to significant variability in quality, potency, and labeling (56).

c. Advocacy for stricter, evidence-based pharmacopoeial standards and mandatory adverse event reporting is a pressing need for patient safety.

4. **Financial and Reimbursement Barriers:** Lack of insurance coverage is a major barrier to access for many patients. Demonstrating cost-effectiveness through research—such as reduced hospitalizations, lower medication use, or improved patient satisfaction—may be necessary to argue for future reimbursement models within value-based care frameworks.

The Path Forward: An Ethically Grounded Model

The ethical integration of Ayurveda into palliative oncology is not about creating a parallel system, but about fostering a **synergistic, patient-centered alliance**. This model is built on:

A. **Transparency** in communication about benefits and risks.

B. **Collaboration** between qualified practitioners from all disciplines involved.

C. **Prioritization** of evidence-informed interventions with favorable risk profiles (e.g., yoga, meditation, select *Rasayana* herbs).

D. **Vigilance** for safety, especially regarding polypharmacy.

E. **Respect** for the patient's cultural and spiritual values as a core component of holistic, dignified care at the end of life.

Future Directions

To advance the responsible and evidence-informed integration of Ayurvedic principles into palliative oncology, a concerted, multi-pronged research and clinical agenda is essential. Moving beyond preliminary studies and anecdotal evidence requires strategic investment in rigorous science, model development, and education. The following priorities outline a roadmap for the field.

1. Prioritizing High-Quality Clinical Research

The foundation of integration must be a robust evidence base generated through scientifically rigorous methodologies.

A. **Definitive Randomized Controlled Trials (RCTs):** There is an urgent need for large, multi-center, Phase III RCTs focusing on specific, standardized Ayurvedic interventions as adjuncts to conventional palliative care. Priority populations should include patients with advanced solid tumors and hematologic malignancies experiencing high symptom burden. Trials should:

a. **Evaluate Specific Interventions:** Test single, well-characterized interventions (e.g., a specific dose of a standardized *Ashwagandha* extract for fatigue, a defined *Triphala* protocol for opioid-induced constipation) rather than complex, variable multi-modal packages initially. This allows for clearer attribution of effects (57).

b. **Utilize Standardized, High-Quality Products:** Employ herbal interventions that are chemically standardized, clinically tested, and produced under GMP conditions to ensure reproducibility and safety (48).

c. **Incorporate Patient-Centered Outcomes:** Primary endpoints should include validated patient-reported outcome measures (PROMs) for target symptoms (e.g., Brief Fatigue Inventory, Edmonton Symptom Assessment System) and quality of life (e.g., FACIT-F, EORTC QLQ-C15-PAL). Secondary endpoints can include biomarkers of inflammation, stress (e.g., cortisol), or immune function where relevant (58).

d. **Include Rigorous Safety Monitoring:** Implement active surveillance for adverse events and potential herb-drug interactions, with systematic reporting.

B. **Comparative Effectiveness Research (CER):** In parallel, CER studies comparing integrated Ayurveda-conventional care to conventional care alone in real-world settings can provide insights into effectiveness, patient satisfaction, and healthcare utilization.

2. Mechanistic and Translational Studies

Building a biological rationale is critical for fostering acceptance within the scientific community and optimizing therapies.

A. **Pharmacological and -Omics Research:** Investigate the mechanisms of action of key Ayurvedic interventions using modern scientific tools.

a. For *Rasayana* herbs like *Ashwagandha* and *Guduchi*, research should explore their effects on pathways relevant to cachexia (e.g., mTOR, NF-κB), inflammation (cytokine modulation), neuroendocrine stress (HPA axis), and mitochondrial function (59).

b. Utilize metabolomics and genomics to explore the biological correlates of *Prakriti* (constitutional typing) and its potential relevance for predicting treatment response or susceptibility to specific symptoms (60).

3. Mixed-Methods and Qualitative Research

Understanding the patient experience and the process of integration is as vital as quantifying outcomes.

A. **Patient-Centered Outcomes Research (PCOR):** Employ mixed-methods designs to deeply understand *why* and *how* patients value integrative care. Qualitative interviews can explore themes of empowerment, holistic support, cultural congruence, and spiritual well-being—outcomes often missed by quantitative scales (61).

B. **Implementation Science Studies:** Investigate the barriers and facilitators to implementing integrative models in diverse healthcare settings (academic centers, community hospices). Focus on workflow, interdisciplinary communication, reimbursement structures, and clinician attitudes (62).

4. Development of Integrative Care Models and Clinical Guidelines

To move from research to practice, standardized frameworks are needed.

A. **Co-Management Protocols:** Develop and pilot-test structured co-management protocols for common scenarios (e.g., "Integrative Protocol for Cancer-Related Fatigue" or "Adjuvant Care for Chemotherapy-Induced Nausea"). These should clearly delineate roles, communication pathways, and monitoring plans between the palliative care team and the Ayurvedic practitioner.

B. **Evidence-Informed Clinical Guidelines:** Professional societies in integrative oncology, palliative care, and Ayurveda should collaborate to develop consensus guidelines. These should address:

a. **Indications:** For which symptoms/populations is there sufficient evidence to recommend consideration of an Ayurvedic intervention?

b. **Safety Contraindications:** Specific warnings for use with certain drug classes, in organ failure, or with severe cytopenias.

c. **Quality Standards:** Recommendations for sourcing and verifying the quality of herbal products.

d. **Referral Criteria:** Guidance on when and how to refer to a qualified Ayurvedic practitioner.

5. Educational and Training Initiatives

Bridging the knowledge gap between disciplines is fundamental to safe collaboration.

A. **Curriculum Development:** Integrate core competencies in T&CM and integrative oncology into the formal curricula of medical schools, nursing programs, and palliative care fellowships. This should include modules on Ayurvedic principles, communication skills for discussing T&CM, and recognition of safety issues (63).

B. **Interprofessional Training:** Create continuing education programs and workshops that bring together palliative care clinicians and Ayurvedic practitioners to learn side-by-side about each other's disciplines, terminology, and scope of practice.

6. Policy and Advocacy

Creating a supportive ecosystem requires engagement with regulatory and policy bodies.

A. **Advocacy for Enhanced Regulation:** Support policies that mandate stricter quality control, standardization, and post-marketing surveillance for Ayurvedic and herbal products to ensure patient safety (56).

B. **Research Funding:** Advocate for dedicated funding streams within national research institutes (e.g., NIH-NCCIH, ICMR) for high-quality clinical trials on integrative approaches in palliative care.

C. **Exploration of Reimbursement Models:** Conduct health economic analyses to evaluate the cost-effectiveness of integrative palliative care models. Data on reduced hospitalizations, emergency department visits, and polypharmacy could inform arguments for insurance coverage and value-based payment models.

Conclusion:

The journey of a patient with advanced cancer is marked by profound multidimensional suffering that extends beyond the biology of the disease to encompass physical distress, psychological anguish, social isolation, and spiritual crisis. Modern palliative care has arisen as an essential discipline to confront this suffering, yet gaps in symptom control and unmet holistic needs persist. This narrative review has explored the potential of Ayurveda, a time-honored system of medicine, to complement and enrich contemporary palliative oncology practice.

The conceptual alignment between these two systems is striking and forms the foundation for meaningful integration. Both are fundamentally **patient-centered and holistic**, recognizing the

individual as a complex, interconnected whole of body, mind, and spirit rather than a mere diagnosis. Both prioritize **symptom alleviation, quality of life, and dignity** as primary treatment goals. Ayurveda's emphasis on individualized constitution (*Prakriti*), balance of functional energies (*Doshas*), and therapeutic modalities ranging from *Rasayana* (rejuvenation) to *Satvavajaya* (mind-spirit therapy) provides a structured, principle-based framework for addressing the very symptom clusters—fatigue, pain, gastrointestinal distress, anxiety—that challenge palliative care clinicians.

The emerging clinical evidence, while preliminary, offers encouraging signals. Studies on *Ashwagandha* for cancer-related fatigue, yoga and meditation for psychological distress, and dietary-herbal strategies for gastrointestinal symptoms suggest tangible benefits. However, this evidence base is constrained by methodological limitations, including small sample sizes, lack of standardization, and inadequate safety monitoring. These limitations do not negate the potential value of Ayurveda but underscore the critical need for a more rigorous, scientific approach to its integration.

The path forward is not one of replacement, but of **synergistic collaboration**. True integration requires navigating significant ethical, cultural, and practical considerations: ensuring informed consent and patient autonomy; vigilantly monitoring for herb-drug interactions and product quality; respecting cultural worldviews with humility; and fostering genuine interdisciplinary teamwork between oncologists, palliative care specialists, and trained Ayurvedic practitioners.

Therefore, the future of this field hinges on a committed, dual agenda. First, it demands **prioritizing high-quality, translational research**—well-designed RCTs, mechanistic studies, and patient-centered outcomes research—to build an incontrovertible evidence base for safety and efficacy. Second, it calls for the **development of practical, ethically grounded clinical models** and guidelines that facilitate safe co-management, cross-disciplinary education, and standardized care pathways.

In conclusion, the principles of Ayurveda offer a valuable and philosophically congruent adjunct to the modern palliative care toolkit. A thoughtful, evidence-informed, and collaborative integrative approach holds significant promise for mitigating the complex suffering inherent in advanced cancer. By thoughtfully weaving together the personalized, holistic wisdom of Ayurveda with the technical expertise and compassionate framework of palliative care, we can move closer to the ultimate goal of oncology: to provide care that truly heals, comforts, and affirms the dignity of the person throughout life's most challenging transition.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71(3):209-249.
2. Hui D, Bruera E. Integrating Palliative Care Into the Trajectory of Cancer Care. *Nat Rev Clin Oncol*. 2016;13(3):159-171.
3. Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. *J Pain Symptom Manage*. 2007;34(1):94-104.
4. World Health Organization. Palliative Care. [Fact sheet]. 2020. Accessed [Date]. https://www.who.int/news-room/fact-sheets/detail/palliative-care
5. Kogan M, Cheng S, Rao S, DeMocker S, Korones DN. Integrating Palliative Care into Primary Care. *Prim Care*. 2019;46(3):447-464.
6. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med*. 2010;363(8):733-742.
7. Haun MW, Estel S, Rücker G, et al. Early palliative care for adults with advanced cancer. *Cochrane Database Syst Rev*. 2017;6(6):CD011129.
8. Keene MR, Heslop IM, Sabesan SS, Glass BD. Complementary and alternative medicine use in cancer: A systematic review. *Complement Ther Clin Pract*. 2019;35:33-47.

9. Yates JS, Mustian KM, Morrow GR, et al. Prevalence of complementary and alternative medicine use in cancer patients during treatment. *Support Care Cancer*. 2005;13(10):806-811.
10. Sharma H, Chandola HM, Singh G, Basisht G. Utilization of Ayurveda in health care: an approach for prevention, health promotion, and treatment of disease. Part 1--Ayurveda, the science of life. *J Altern Complement Med*. 2007;13(9):1011-1019.
11. Rotti H, Guruprasad KP, Nayak J, et al. Immunophenotyping of normal individuals classified on the basis of human dosha prakriti. *J Ayurveda Integr Med*. 2014;5(1):43-49.
12. Dhruva A, Hecht FM, Miaskowski C, et al. Correlating traditional Ayurvedic and modern medical perspectives on cancer: results of a qualitative study. *J Altern Complement Med*. 2014;20(5):364-370.
13. Hankey A. The scientific value of Ayurveda. *J Altern Complement Med*. 2005;11(2):221-225.
14. Rotti H, Guruprasad KP, Nayak J, et al. Immunophenotyping of normal individuals classified on the basis of human dosha prakriti. *J Ayurveda Integr Med*. 2014;5(1):43-49.
15. Patwardhan B. The history of the discovery of blood circulation: unrecognized contributions of Ayurveda masters. *Adv Physiol Educ*. 2012;36(2):77-82.
16. Mishra LC, Singh BB, Dagenais S. Ayurveda: a historical perspective and principles of the traditional healthcare system in India. *Altern Ther Health Med*. 2001;7(2):36-42.
17. Chandola HM. Role of Agni in the Pathogenesis of Diabetes. *Anc Sci Life*. 1985;4(3):164-168.
18. Patil VC, Baghel MS, Thakar AB. A review of the concept of Samprapti (Pathogenesis) in Ayurveda. *AYU*. 2011;32(3):314-319.
19. Telles S, Naveen KV, Balkrishna A. Use of Ayurveda in promoting dental health and preventing dental caries. *Indian J Dent Res*. 2009;20(4):466.
20. Narayana A, Subhose V. Standardization of Ayurvedic polyherbal formulations: A review of current methodologies. *J Ayurveda Integr Med*. 2015;6(1):13-19.
21. Rastogi S. Building bridges between Ayurveda and modern science. *Int J Ayurveda Res*. 2010;1(1):41-46.
22. Kessler CS, Michalsen A. The role of whole medical systems in global medicine. *Complement Med Res*. 2012;19(2):65-66.
23. Thakar VJ. Diagnosis and management of pain in Ayurveda. *Anc Sci Life*. 1986;5(3):169-175.
24. Kumar S, Prasad A, Iyengar S. Effect of Abhyanga (oil massage) on physiological and psychological parameters in healthy volunteers. *J Ayurveda Integr Med*. 2021;12(3):529-533.
25. Pratte MA, Nanavati KB, Young V, Morley CP. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera). *J Altern Complement Med*. 2014;20(12):901-908.
26. Siddiqui MZ. Boswellia serrata, a potential antiinflammatory agent: an overview. *Indian J Pharm Sci*. 2011;73(3):255-261.
27. Singh BB, Mishra LC, Vinjamury SP. The role of guggulu in inflammatory disorders. *Altern Ther Health Med*. 2003;9(2):74-80.
28. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. *AAPS J*. 2013;15(1):195-218.
29. Balachandran P, Govindarajan R. Cancer--an Ayurvedic perspective. *Pharmacol Res*. 2005;51(1):19-30.
30. Biswal BM, Sulaiman SA, Ismail HC, Zakaria H, Musa KI. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. *Integr Cancer Ther*. 2013;12(4):312-322.
31. Sharma U, Bala M, Kumar N, et al. Anti-fatigue activity of Tinospora cordifolia in experimentally induced fatigue. *Pharmacognosy Res*. 2012;4(4):223-226.
32. Cramer H, Lauche R, Klose P, et al. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. *Cochrane Database Syst Rev*. 2017;1(1):CD010802.
33. Lad V. Ayurveda: The Science of Self-Healing. Lotus Press; 1984.

34. Marx W, Ried K, McCarthy AL, et al. Ginger-Mechanism of action in chemotherapy-induced nausea and vomiting: A review. *Crit Rev Food Sci Nutr*. 2017;57(1):141-146.
35. Peterson CT, Denniston K, Chopra D. Therapeutic Uses of Triphala in Ayurvedic Medicine. *J Altern Complement Med*. 2017;23(8):607-614.
36. Dwivedi V, Anandan EM, Mony RS, et al. In vitro effect of Brahmi ghrita, an Ayurvedic formulation, on lipopolysaccharide-induced changes in cyclooxygenase-2 and inducible nitric oxide synthase expression in rat glioma cells. *J Ayurveda Integr Med*. 2012;3(2):73-77.
37. Mooventhan A, Nivethitha L. Evidence based effects of yoga in neurological disorders. *J Clin Neurosci*. 2017;43:61-67.
38. Cillessen L, Johannsen M, Speckens AEM, Zachariae R. Mindfulness-based interventions for psychological and physical health outcomes in cancer patients and survivors: A systematic review and meta-analysis of randomized controlled trials. *Psychooncology*. 2019;28(12):2257-2269.
39. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. *Indian J Psychol Med*. 2012;34(3):255-262.
40. Agarwal A, Diwanay S, Patki P, Patwardhan B. Studies on immunomodulatory activity of *Withania somnifera* (Ashwagandha) extracts in experimental immune inflammation. *J Ethnopharmacol*. 1999;67(1):27-35.
41. Dhruva A, Miaskowski C, Abrams D, et al. Ayurveda for breast cancer survivors: a pilot randomized controlled trial. *Integr Cancer Ther*. 2015;14(3):242-250.
42. Buffart LM, van Uffelen JG, Riphagen II, et al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. *BMC Cancer*. 2012;12:559.
43. Stough C, Downey LA, Lloyd J, et al. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. *Phytother Res*. 2008;22(12):1629-1634.
44. Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial. *Phytomedicine*. 2003;10(1):3-7.
45. Kulkarni SK, Dhir A. Withania somnifera: an Indian ginseng. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32(5):1093-1105.
46. Warrier M. Seekership, Spirituality and Self-Discovery: Ayurveda Trainees in Britain. *Asian Med (Leiden)*. 2009;4(2):423-451.
47. Rastogi S, Chiappelli F, Ramchandani MH, Singh RH. The scope of Ayurveda in integrative oncology. In: *Evidence-Based Practice in Complementary and Alternative Medicine*. Springer; 2012:165-179.
48. Narayana A, Subhose V. Standardization of Ayurvedic polyherbal formulations: A review of current methodologies. *J Ayurveda Integr Med*. 2015;6(1):13-19.
49. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. *Evid Based Complement Alternat Med*. 2005;2(4):465-473.
50. Posadzki P, Watson LK, Ernst E. Adverse effects of herbal medicines: an overview of systematic reviews. *Clin Med (Lond)*. 2013;13(1):7-12.
51. Scott GN, Elmer GW. Update on natural product--drug interactions. *Am J Health Syst Pharm*. 2002;59(4):339-347.
52. Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. *JAMA*. 2008;300(8):915-923.
53. Canaway R, Manderson L. Quality of life, perceptions of health and illness, and complementary therapy use among people with type 2 diabetes and cardiovascular disease. *J Altern Complement Med*. 2013;19(11):882-890.

54. Dwyer J, Orr R. The ethics of traditional and complementary medicine. In: *The Oxford Textbook of Clinical Research Ethics*. Oxford University Press; 2008.
55. Frenkel M, Ben-Arye E, Cohen L. Communication in cancer care: discussing complementary and alternative medicine. *Integr Cancer Ther*. 2010;9(2):177-185.
56. Gogtay NJ, Bhatt HA, Dalvi SS, Kshirsagar NA. The use and safety of non-allopathic Indian medicines. *Drug Saf*. 2002;25(14):1005-1019.
57. Fønnebø V, Grimsgaard S, Walach H, et al. Researching complementary and alternative treatments--the gatekeepers are not at home. *BMC Med Res Methodol*. 2007;7:7.
58. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. *J Clin Oncol*. 2012;30(34):4249-4255.
59. Singh N, Bhalla M, de Jager P, Gilca M. An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda. *Afr J Tradit Complement Altern Med*. 2011;8(5 Suppl):208-213.
60. Prasher B, Negi S, Aggarwal S, et al. Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda. *J Transl Med*. 2008;6:48.
61. Verhoef MJ, Vanderheyden LC, Dryden T, Mallory D, Ware MA. Evaluating complementary and alternative medicine interventions: in search of appropriate patient-centered outcome measures. *BMC Complement Altern Med*. 2006;6:38.
62. Bauer MS, Damschroder L, Hagedorn H, Smith J, Kilbourne AM. An introduction to implementation science for the non-specialist. *BMC Psychol*. 2015;3:32.
63. Ben-Arye E, Frenkel M, Klein A, Scharf M. Attitudes toward integration of complementary and alternative medicine in primary care: perspectives of patients, physicians and complementary practitioners. *Patient Educ Couns*. 2008;70(3):395-402.